poliovirus vaccine, trivalent diphtheriaÐtetanusÐpertussis vaccine, bivalent diphtheriaÐtetanus vaccine, bivalent tetanusÐdiphtheria vaccine, monovalent tetanus vaccine, trivalent measlesÐ mumpsÐrubella vaccine, Haemophilus influenzae group b (Hib) vaccines, hepatitis B virus vaccine and other vaccines. For 329 (75%) of the cases and 334 (76%) of the controls among the 439 matched pairs, the mother provided vaccination records, and the physician was not contacted. With the motherÕs permission, a medical-record request was filed with the subjectÕs primary physician, requesting details and dates of vaccination for the remaining subjects.
Vaccination data were sought but not obtained from 158 of the 788 cases whose mothers were interviewed in-person, of whom 63 were due to maternal refusal, and 94 were due to physician refusal or non-response. Likewise, 84 maternal refusals and 63 physician refusals or non-responses were the main reasons for the 149 controls without vaccination data among the 699 controls whose mothers were interviewed in-person. Vaccination data were coded up to the date of diagnosis for cases, and up to the date of interview for controls.
To ensure that the case and control within each pair were observed for the same length of time, we censored the vaccination data by adopting a common Ôcut-off-ageÕ (the lesser of the age at diagnosis for the case or the age at interview for the control) for both members of each matched pair, excluding from analysis any vaccine doses received after the cut-off age. We calculated relative risks and 95% confidence intervals for ALL following exposure to each vaccine (ever vs never vaccinated). We also evaluated number of doses of vaccine received, age at first dose, age at last dose, time between first dose of each vaccine and diagnosis, and time between last dose of each vaccine and diagnosis. Since none of these analyses contributed additional useful information, only the ever-versus never-vaccinated results are presented here.
Relative risks (RR) and 95% confidence intervals (CI) were calculated by conditional logistic regression (Breslow and Day, 1980 ) using a matched-pairs design and adjusting for age (in years) at censoring, year of birth, sex, race, family income and parental education, as shown in Table 1 . For nine subjects (seven cases and two controls) with unknown family income, the median family income among controls was imputed as the subjectÕs family income. For the fathers of 31 subjects (12 cases and 19 controls) whose level of education was unknown, the median education level from the controls was imputed. Since early day-care or preschool attendance has been linked with decreased risk of ALL in prior studies (Petridou et al, 1993) , we adjusted for these variables as well.
Monovalent injected vaccines to protect against hepatitis B virus, tetanus and poliovirus were received by fewer than 1% of subjects, and monovalent vaccines to protect subjects from Neisseria meningitidis, Mycobacterium tuberculosis, varicella, or mumps, were received by very few subjects. Therefore, none of these vaccines were separately analysed. Although few subjects received monovalent or bivalent vaccines against tetanus and/or diphtheria, summary variables were created to integrate all possible vaccine doses containing tetanus or diphtheria toxoids.
The first Hib vaccine approved by the US Food and Drug Administration was a polysaccharide vaccine licensed in April 1985. A single dose was to be administered at the age of 24 months (Advisory Committee on Immunization Practices, 1985), or at 18 months for those in day-care, since early day-care attendance was linked with increased risk of invasive Hib infection in several US studies (Redmond and Pichichero, 1984; Istre et al, 1985; Cochi et al, 1986) . The first conjugate vaccine was licensed in December 1987; a single dose was to be administered at the age of 18 months (Advisory Committee on Immunization Practices, 1988). The first doses of conjugate vaccine were shipped in 1988 (Adams et al, 1993) . In 1990, two conjugate Hib vaccines, developed subsequent to the first formulation, were recommended for use in four doses at the ages of 2, 4, 6 and 15 months (Advisory Committee on Immunization Practices, 1991).
Since the vaccine records provided by mothers or physicians did not specify the type of Hib vaccine, any dose administered before 1 January 1988 was assumed to be polysaccharide Hib vaccine for purposes of this study; doses administered on or after that date were assumed to be the conjugate Hib vaccine. Only 29 subjects (14 cases and 15 controls) received more than one dose of Hib vaccine; 28 of these were born after 1988 and presumably received only conjugate vaccine. Due to small numbers, it was deemed impossible to assess the effect of multiple doses of Hib vaccine. No subject received Hib vaccine doses both before and after 1 January 1988. For the analysis of Hib vaccine effects, the polysaccharide and conjugate vaccine types were modelled simultaneously, and the reference group included only those subjects who received neither type.
RESULTS
Demographic data on cases and controls (Table 1) show that cases came from families with lower income and parental education than controls, but there were few differences in year of birth, age at censoring, or attendance at day-care or preschool. Results for individual vaccines, as well as for the two summary variables reflecting all exposures to tetanus or diphtheria toxoids, are shown in Table 2 . The vast majority of subjects received at least one dose of three major vaccines: oral poliovirus (98%), diphtheriaÐtetanusÐpertussis (97%), and measlesÐmumpsÐrubella (90%). None of these vaccines significantly altered the risk of subsequent ALL. Hib vaccine in some form was received by 53% of controls versus 47% of cases (RR = 0.73; 95% CI 0.50Ð1.06). Similar proportions of cases (12%) and controls (11%) received the polysaccharide Hib vaccine (RR = 1.13; 95% CI 0.64Ð1.98). A higher proportion of controls (41%) than cases (35%) received the conjugate Hib vaccine; thus, the conjugate Hib vaccine was associated with a significantly reduced risk of subsequent ALL (RR = 0.57; 95% CI 0.36Ð0.89). When the effect of Hib vaccination was analysed for three different birth cohorts (pre-1984, 1984Ð1986, and post-1986) , the reduced risk was seen only among children born after 1986, who presumably received only the conjugate Hib vaccine (data not shown). Neither age at vaccination nor interval between vaccination and diagnosis affected the risk of ALL following any of the vaccines; nor did number of doses of OPV or DTP (data not shown).
DISCUSSION
Several vaccines commonly administered to US infants have been reported to reduce the risk of subsequent childhood leukaemia in four of the five previously-cited studies. Our study is one of the largest and most comprehensive evaluations of the relationship between infant vaccinations and childhood ALL. It is also distinguished by reliance on written vaccination records, rather than maternal recall. In addition, our study is one of the first to investigate the relationship between Hib vaccines and childhood ALL. Administration of the conjugate Hib vaccine was associated with a reduced risk of subsequent childhood ALL. The polysaccharide Hib vaccine exhibited no such inverse association. In the conjugate vaccine, the Hib capsular polysaccharide is covalently bound (i.e. ÔconjugatedÕ) to a highly immunogenic protein antigen, yielding an antibody response which begins earlier (at a younger age), rises higher, and lasts longer than that which follows vaccination with the unconjugated polysaccharide (Wenger et al, 1989) . Although the mechanism of any anti-leukaemic effect of vaccination remains to be elucidated, it is at least plausible that such an effect would be more pronounced with the conjugate vaccine.
In contrast with four previous studies (Kneale et al, 1986; McKinney et al, 1987; Nishi and Miyake, 1989; Kaatsch et al, 1996) , our data provide no evidence of a reduced ALL risk following vaccination with DTP, MMR, or OPV. Our failure to detect such inverse associations may be due to a lack of statistical power, because DTP, MMR and OPV were nearly universal among both cases and controls. There are other possible reasons for this discrepancy, however. Our study differed in several methodologic aspects from previous investigations. Only one previous study (Innis, 1965) obtained vaccine data from written records, only one (Kneale et al, 1986 ) included more cases, and only two (Nishi and Miyake, 1989; Kaatsch et al, 1996) focused specifically on ALL. While four of the previous studies (Kneale et al, 1986; McKinney et al, 1987; Nishi and Miyake, 1989; Kaatsch et al, 1996) utilized age-matched controls, only one (Kaatsch et al, 1996) adjusted for socioeconomic status. Only one previous study (Nishi and Miyake, 1989) separately reported the relative risks and 95% confidence intervals for childhood leukaemia following specific vaccinations; other studies reported the effect of specific vaccines on all malignancies combined (Kneale et al, 1986) , and/or the effect of vaccines in general on childhood leukaemia in particular (Innis, 1965; Kneale et al, 1986; McKinney et al, 1987; Kaatsch et al, 1996) .
The apparent reduced risk of ALL after receiving conjugate Hib vaccine may have been a chance finding, perhaps due to multiple comparisons. Another possible explanation of the results for Hib vaccine may be bias, since controls selected using random-digit dialing were more likely to be offspring of parents with higher education and/or family income compared with cases (Kleinerman et al, 1997) . While this may explain the tendency of the controls to have more vaccinations, the association between conjugate Hib vaccine and ALL persisted after statistical adjustment for family income and parental education, and no such inverse association was observed for any other vaccine. Confounding by socioeconomic status may be more plausible for the Hib vaccine than for other vaccines, since parents of higher socioeconomic status may have been more inclined to avail themselves of the newlyintroduced, voluntary Hib vaccine.
Because both age and calendar time are strongly related to Hib vaccination rate, we controlled for both temporal factors. Although we assumed that only the conjugate Hib vaccine was administered after 31 December 1987, the polysaccharide vaccine might have been used sporadically. However, such misclassification would have reduced the observed inverse association. Other important limitations of our study were the use of random-digit dialing to identify controls, and the attendant low response rate (only 50%) for controls. The response rate was lower than that for other components of the study because written vaccination records with dates of vaccination were required; nonetheless, because of the requirement for written records, this is one of the largest and most stringent investigations to date of the role of vaccinations in childhood ALL. We believe that our findings justify a more definitive investigation of this question because of the important scientific and public health implications if our findings for the Hib vaccine are confirmed. Future studies should utilize population-based cases and controls matched as closely as possible on date of birth, with vaccination histories obtained from medical records. Cohort studies comparing the incidence of leukaemia among subjects who participated in randomized clinical trials of the conjugate Hib vaccine, or other vaccines, would offer stronger evidence to support or refute a reduced ALL risk following vaccination.
